CPQ and neoplasm: Following assembly with AE, 0.25 and 0.5 mg/kg enediyne-energized CDR3-LDP-AE fusion protein demonstrated tumor inhibition rates of 78.8 and 87.1%, respectively (P<0.05 compared with those of CDR3-LDP and lidamycin).